Correspondence 0001171843-23-004226 from Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc.
Date: June 28, 2023 · CIK: 0000882361 · Accession: 0001171843-23-004226
AI Filing Summary & Sentiment
File numbers found in text: 333-272752
Show Raw Text
CORRESP
1
filename1.htm
Aptose Biosciences, Inc.
251 Consumers Road, Suite 1105
Toronto, Ontario, Canada M2J 4R3
June 28, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Dillon Hagius
Re: Aptose Biosciences, Inc. – Registration
Statement on Form S-1 (File No. 333-272752)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form
S-1 (File No. 333-272752), as amended (the “Registration Statement”) of Aptose Biosciences, Inc. We respectfully request that
the Registration Statement become effective as of 5:00 p.m., Eastern Time, on June 30, 2023, or as soon thereafter as is reasonably practicable.
Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Dorsey & Whitney LLP,
by calling Dan Miller at (604) 630-5199.
Very truly yours,
Aptose Biosciences, Inc.
By:
/s/ William G. Rice
Name:
William G. Rice
Title:
Chief Executive Officer